Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 210 participants.

Also called NCT02831088

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 210 participants (planned count) (from the registry)
Sponsor
  • GNT Pharma Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02831088
Other papers using this trial's data
  • Nelonemdaz for Patients With Acute Ischemic Stroke Undergoing Endovascular Reperfusion Therapy: A Randomized Phase II Trial Stroke, 2022-11 DOI, PubMed 36065810, PMC9586831 In the PMC Open Access subset under CC BY-NC-ND.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02831088. Randomized; triple masking; primary purpose treatment. Start 2016-07 (registry gives no type); primary completion 2018-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
Acronym
SONIC
Intervention (Drug)
Neu2000KWL High-does group
Intervention (Drug)
Neu2000KWL Low-does group
Intervention (Drug)
Placebo
Lead sponsor
GNT Pharma (class: industry)

Record details

Record id
cardio:ct-nct02831088
Content hash
d77ff4ab4082983fced211ac87f7b1abcbc188819e69b614e9dfd90934fa62ae